Combination therapy

Details for Australian Patent Application No. 2004255023 (hide)

Owner AstraZeneca AB

Inventors Wedge, Stephen Robert

Agent Davies Collison Cave

Pub. Number AU-B-2004255023

PCT Pub. Number WO2005/004871

Priority 0316123.9 10.07.03 GB

Filing date 7 July 2004

Wipo publication date 20 January 2005

Acceptance publication date 27 September 2007

International Classifications

A61K 31/165 (2006.01) - having aromatic rings, e.g. colchicine, atenolol, progabide

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

19 January 2006 PCT application entered the National Phase

  PCT publication WO2005/004871 Priority application(s): WO2005/004871

27 September 2007 Application Accepted

  Published as AU-B-2004255023

24 January 2008 Standard Patent Sealed

3 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004255024-Cancer combination therapy comprising AZD2171 and ZD1839

2004255022-Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability